Navigation Links
Neurocrine Biosciences Reports Third Quarter 2011 Results
Date:10/31/2011

related to advancing elagolix into Phase II clinical trials in uterine fibroids and a $20.0 million milestone related to the outcome of an elagolix pre-Phase III meeting with the FDA for endometriosis. The increase in year-to-date revenue is a result of these milestones, as well as a full nine months of revenue recognition under the collaboration agreements with Abbott and Boehringer Ingelheim, for our GnRH and GPR119 programs, respectively. The Company entered into both of these collaboration agreements in June of 2010.

Research and development expenses decreased to $7.5 million during the third quarter of 2011 compared to $8.2 million for the same period in 2010. Year-to-date research and development expenses for 2011 were $22.9 million compared to $23.1 million for the first nine months of 2010. This decrease in expense is primarily due to the continued transition of the elagolix workload from the Company to Abbott, offset by an increase in external development expenses for the Company's VMAT2 program.General and administrative expenses increased to $3.8 million during the third quarter of 2011 compared with $3.6 million for the same period last year. For the nine months ended September 30, 2011, general and administrative expenses were $9.8 million, compared to $10.0 million for the first nine months of 2010.

Other income was $0.9 million during the third quarter of both 2011 and 2010. Other income decreased from $3.1 million of income during the first nine months of 2010 to $2.8 million of other income for the first nine months of 2011. This change resulted primarily from a one-time $0.5 million gain recognized on auction rate securities in 2010.

Pipeline HighlightsElagolix UpdateElagolix Phase III trials for endometriosis are planned to start in the fourth quarter of 2011, with Phase II trials assessing elagolix in uterine fibroids initiated in the third quarter of 2011.

Additionally, multiple abstracts and datasets fro
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
6. Neurocrine Biosciences Reports Third Quarter 2008 Results
7. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
9. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Announces Work Force Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Houston, Texas (PRWEB) , ... July 03, 2015 ... ... search firm, highly-regarded by Fortune 500 companies and professional service industries alike-- typically ... aimed to make clients laugh, honor a good cause and break from their ...
(Date:7/3/2015)... 2015 Forskere kan ... in Science", som finner sted i ... nett, på  http://www.openinnovationinscience.at , og søknadsperioden varer ... De to største utfordringene innen helsevitenskapen er ... forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, i ...
(Date:7/2/2015)... ... ... in countless labs for decades. In the past, people had to go to a ... a daunting and tiring process looking at endless data tables and charts. Often time’s, ... catalog structure. , Now thanks to FireflySci, scientists are throwing away those old books and ...
(Date:7/2/2015)... GLASGOW, Scotland , July 2, 2015 ...   Bio-tech procurement company Amici Procurement has ... IOM) to help it move to Office 365. ... Procurement provides small to medium-sized companies in the ... with all aspects of the purchasing cycle to help ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2Biotech Procurement Company Moves to Office 365 with iomart 2
... INC. (Nasdaq: VION ) today announced that the ... 7.75% Convertible Senior Notes due,2012 (the "Notes"). The aggregate ... Company paid $2,260,416.67 in interest through the issuance of,shares ... in,2,539,200 shares of Common Stock, based on today,s closing ...
... Ltd. (NASDAQ: HCTL ), today announced unaudited results for ... Revenues for the first six months of 2007 were ... of 2006. The gross profit for the,first half of the ... in 2006. The net loss for such period was $(319) ...
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), ... Listings Qualifications Department informed the Company that the,market ... million for 10,consecutive days, which is the requirement ... to Marketplace Rule 4450(b)(1)(A). Nasdaq,also informed the Company ...
Cached Biology Technology:Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 3Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results 2Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 4
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... preserve grapes could help prevent allergies and boost healthy compounds ... Industry, the magazine of the SCI. The same technique could ... without the added sulphites that can cause asthma and other ... in storage for months and are usually treated with sulphur ...
... Researchers at Columbia University’s Mailman School of Public Health ... cancer. Using DNA isolated from serum samples as ... tumor suppressor genes that have been associated with the ... to prospectively examine potential biomarkers for early detection of ...
... normally used to treat insomnia, temporarily improved brain function ... in which the person is alert but cannot speak ... and eat without assistance after receiving the drug for ... the March 2007 issue of Annals of Neurology ( ...
Cached Biology News:Grape expectations for healthier wine 2Mailman School of Public Health researchers report blood DNA can be early predictor of liver cancer 2Insomnia drug can improve brain function 2
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
... High Performance, 5 ml. The same ... HiTrap Streptavidin columns for fast, reliable ... into Tricorn 5/50 GL, XK 16/20, ... purifications are required.Extremely useful for exploiting ...
... Immunogen: Synthetic peptide derived ... human SENP1. Specificity: Specific ... SENP1. Reactivity: Human (positive ... Hep2 cell lysates HL-60 cell ...
...
Biology Products: